🚀 VC round data is live in beta, check it out!
Dr. Soliman Abdul Kader Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dr. Soliman Abdul Kader and similar public comparables like Huaxia Eye Hospital Group, MLP Sağlık, Select Medical, Akdital and more.
Dr. Soliman Abdul Kader Overview
About Dr. Soliman Abdul Kader
Dr Soliman Abdul Kader Fakeeh Hospital Co is a company whose principal activities include managing, establishing, and operating hospitals, clinics, medical, educational, and training centers. In addition to the above, the company is also managing and operating medical services, analysis and radiology laboratory, and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment, and software-related services. The group has three reportable segments, including medical services, which generates maximum revenue, education, trading, retail, and others. Geographically, it principally operates in the Kingdom of Saudi Arabia.
Founded
1978
HQ
Employees
2.7K
Website
Sectors
Financials (LTM)
EV
$2B
Dr. Soliman Abdul Kader Financials
Dr. Soliman Abdul Kader reported last 12-month revenue of $854M and EBITDA of $140M.
In the same LTM period, Dr. Soliman Abdul Kader generated $140M in EBITDA and $82M in net income.
Revenue (LTM)
Dr. Soliman Abdul Kader P&L
In the most recent fiscal year, Dr. Soliman Abdul Kader reported revenue of $745M and EBITDA of $146M.
Dr. Soliman Abdul Kader expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $854M | XXX | $745M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $187M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $140M | XXX | $146M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $82M | XXX | $77M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $725K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dr. Soliman Abdul Kader Stock Performance
Dr. Soliman Abdul Kader has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Dr. Soliman Abdul Kader's stock price is $9.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDr. Soliman Abdul Kader Valuation Multiples
Dr. Soliman Abdul Kader trades at 2.7x EV/Revenue multiple, and 16.6x EV/EBITDA.
EV / Revenue (LTM)
Dr. Soliman Abdul Kader Financial Valuation Multiples
As of April 19, 2026, Dr. Soliman Abdul Kader has market cap of $2B and EV of $2B.
Equity research analysts estimate Dr. Soliman Abdul Kader's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr. Soliman Abdul Kader has a P/E ratio of 26.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 16.6x | XXX | 15.9x | XXX | XXX | XXX |
| EV/EBIT | 26.1x | XXX | 24.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 12.4x | XXX | XXX | XXX |
| P/E | 26.0x | XXX | 27.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (97.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dr. Soliman Abdul Kader Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dr. Soliman Abdul Kader Margins & Growth Rates
Dr. Soliman Abdul Kader's revenue in the last 12 month grew by 15%.
Dr. Soliman Abdul Kader's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Dr. Soliman Abdul Kader's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr. Soliman Abdul Kader's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dr. Soliman Abdul Kader Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | (9%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dr. Soliman Abdul Kader Public Comps
See public comps and valuation multiples for other Hospitals & Clinics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dr. Soliman Abdul Kader | XXX | XXX | XXX | XXX | XXX | XXX |
| Huaxia Eye Hospital Group | XXX | XXX | XXX | XXX | XXX | XXX |
| MLP Sağlık | XXX | XXX | XXX | XXX | XXX | XXX |
| Select Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Akdital | XXX | XXX | XXX | XXX | XXX | XXX |
| Siloam Hospitals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Soliman Abdul Kader M&A Activity
Dr. Soliman Abdul Kader acquired XXX companies to date.
Last acquisition by Dr. Soliman Abdul Kader was on XXXXXXXX, XXXXX. Dr. Soliman Abdul Kader acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dr. Soliman Abdul Kader
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDr. Soliman Abdul Kader Investment Activity
Dr. Soliman Abdul Kader invested in XXX companies to date.
Dr. Soliman Abdul Kader made its latest investment on XXXXXXXX, XXXXX. Dr. Soliman Abdul Kader invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dr. Soliman Abdul Kader
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dr. Soliman Abdul Kader
| When was Dr. Soliman Abdul Kader founded? | Dr. Soliman Abdul Kader was founded in 1978. |
| Where is Dr. Soliman Abdul Kader headquartered? | Dr. Soliman Abdul Kader is headquartered in Saudi Arabia. |
| How many employees does Dr. Soliman Abdul Kader have? | As of today, Dr. Soliman Abdul Kader has over 2K employees. |
| Is Dr. Soliman Abdul Kader publicly listed? | Yes, Dr. Soliman Abdul Kader is a public company listed on Tadawul. |
| What is the stock symbol of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader trades under 4017 ticker. |
| When did Dr. Soliman Abdul Kader go public? | Dr. Soliman Abdul Kader went public in 2024. |
| Who are competitors of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader main competitors are Huaxia Eye Hospital Group, MLP Sağlık, Select Medical, Akdital. |
| What is the current market cap of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's current market cap is $2B. |
| What is the current revenue of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's last 12 months revenue is $854M. |
| What is the current revenue growth of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Dr. Soliman Abdul Kader? | Current revenue multiple of Dr. Soliman Abdul Kader is 2.7x. |
| Is Dr. Soliman Abdul Kader profitable? | Yes, Dr. Soliman Abdul Kader is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr. Soliman Abdul Kader? | Dr. Soliman Abdul Kader's last 12 months EBITDA is $140M. |
| What is Dr. Soliman Abdul Kader's EBITDA margin? | Dr. Soliman Abdul Kader's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Dr. Soliman Abdul Kader? | Current EBITDA multiple of Dr. Soliman Abdul Kader is 16.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.